Trial Profile
A Phase 3, Randomized, Double-blind Study of BMS-986205 Combined with Nivolumab versus Nivolumab in Participants with Metastatic or Unresectable Melanoma that is Previously Untreated
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Jun 2022
Price :
$35
*
At a glance
- Drugs Linrodostat (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Registrational
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 23 Feb 2022 This trial has been discontinued in Japan, according to Japan Pharmaceutical Information Center - Clinical Trials Information record.
- 19 Mar 2021 Status changed from active, no longer recruiting to completed.
- 14 Nov 2020 This trial has been completed in Netherlands Republic